Breast Cancer Trial Results
Denosumab May Help Prevent Bone Loss Related to Use of Aromatase Inhibitors
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
Paclitaxel Versus Docetaxel for Early Breast Cancer
(Posted: 04/30/2008) - Weekly treatment with the drug paclitaxel (Taxol®) in addition to standard chemotherapy proved most effective in extending overall survival among women with early-stage breast cancer, according to the April 17, 2008, New England Journal of Medicine.
Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial
(Posted: 03/26/2008) - Postmenopausal women taking the drug anastrozole (Arimidex®) to prevent a recurrence of breast cancer suffered more bone loss than women taking tamoxifen (Nolvadex®), even while anastrozole provided better protection against relapse, according to the March 1, 2008, Journal of Clinical Oncology.
Anthracyclines Improve Survival for HER2-Positive, But Not HER2-Negative, Breast Cancer
(Posted: 01/30/2008) - Chemotherapy with an anthracycline drug such as doxorubicin or epirubicin extends survival for women with HER2-positive, but not HER2-negative, breast cancer, according to a meta-analysis published in the Jan. 2, 2008, Journal of the National Cancer Institute.
(Posted: 09/11/2008) - Treatment with the experimental drug denosumab increased bone density in postmenopausal women taking aromatase inhibitors to prevent a recurrence of breast cancer, according to a report published online August 25, 2008, by the Journal of Clinical Oncology.
Taxane Combinations Marginally Better than Anthracyclines for Metastatic Breast Cancer
(Posted: 05/21/2008) - Combined data from eleven clinical trials showed that patients receiving taxanes for newly diagnosed metastatic breast cancer did marginally better than patients receiving anthracyclines, according to the April 20, 2008, Journal of Clinical Oncology.
Paclitaxel Versus Docetaxel for Early Breast Cancer
(Posted: 04/30/2008) - Weekly treatment with the drug paclitaxel (Taxol®) in addition to standard chemotherapy proved most effective in extending overall survival among women with early-stage breast cancer, according to the April 17, 2008, New England Journal of Medicine.
Anastrozole, Tamoxifen, and Bone Loss on the ATAC Trial
(Posted: 03/26/2008) - Postmenopausal women taking the drug anastrozole (Arimidex®) to prevent a recurrence of breast cancer suffered more bone loss than women taking tamoxifen (Nolvadex®), even while anastrozole provided better protection against relapse, according to the March 1, 2008, Journal of Clinical Oncology.
Anthracyclines Improve Survival for HER2-Positive, But Not HER2-Negative, Breast Cancer
(Posted: 01/30/2008) - Chemotherapy with an anthracycline drug such as doxorubicin or epirubicin extends survival for women with HER2-positive, but not HER2-negative, breast cancer, according to a meta-analysis published in the Jan. 2, 2008, Journal of the National Cancer Institute.
